Humacyte Announces Fourth Quarter and Year End 2025 Financial Results and Provides Business Update

Core Insights - Humacyte, Inc. reported total revenues of $0.5 million for Q4 2025 and $2.0 million for the full year, with significant growth in product sales and collaborations [1][11] - The company received a purchase commitment of $1.475 million for a clinical evaluation program in Saudi Arabia, indicating strong international interest in its product, Symvess [1][4] - A Marketing Authorization Application for Symvess has been submitted to the Israel Ministry of Health, expanding its market reach [1][5] - The U.S. Department of Defense has authorized funding for the procurement of bioengineered blood vessels, highlighting the product's relevance for military applications [1][4] - An important milestone is expected in Q2 2026 with the announcement of top-line interim results from the V012 Phase 3 study in hemodialysis access [1][3] Financial Performance - Revenue for Q4 2025 was $0.5 million, with $0.4 million from U.S. sales of 25 Symvess units and $0.1 million from a research collaboration [11][29] - For the full year 2025, revenue totaled $2.0 million, with $1.4 million from U.S. sales of 61 Symvess units and $0.6 million from research collaborations [11][29] - Cost of goods sold was $9.1 million for Q4 2025 and $9.7 million for the full year, including an $8.9 million inventory reserve [11][29] - Research and development expenses decreased to $14.6 million in Q4 2025 from $20.7 million in Q4 2024, reflecting a shift towards commercial operations [11][29] - The net loss for Q4 2025 was $24.8 million, compared to a net loss of $20.9 million in Q4 2024, while the annual net loss decreased to $40.8 million from $148.7 million [11][29] Product Development and Pipeline - The company is advancing its coronary tissue engineered vessel (CTEV) towards a first-in-human study in CABG, with plans to initiate clinical trials in the second half of 2026 [3][8] - The V012 Phase 3 study is designed to assess the efficacy and safety of the acellular tissue engineered vessel (ATEV) for hemodialysis, with interim results expected by early June 2026 [9][11] - Long-term efficacy and safety data for Symvess have been published, demonstrating its durability and low infection rates in various applications [9][11] Market Expansion - Humacyte is actively expanding the commercialization of Symvess in international markets, with a focus on education and evaluation programs for surgeons in Saudi Arabia [3][4] - The company has received multiple Value Analysis Committee (VAC) approvals, with 27 hospitals having ordered Symvess, indicating growing acceptance in the U.S. market [4][11]